Clear cell sarcoma
MONDO:0002926A rare malignant neoplasm with melanocytic differentiation characterized by the presence of polygonal or spindle shaped clear cells. This sarcoma usually affects the tendons and aponeuroses and is associated with a poor prognosis due to recurrences and metastases.
Also known as: chordoid sarcoma, clear cell sarcoma (morphologic abnormality), clear cell sarcoma - not kidney, clear cell sarcoma of soft parts, clear cell sarcoma of soft tissue, clear cell sarcoma/malignant melanoma of soft parts (excluding clear cell sarcoma of the kidney), malignant melanoma of the soft parts, melanoma, malignant, of soft parts
2829 clinical trials for this condition and its sub-types, 14 tagged with Clear cell sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Clear cell sarcoma
-
Clear cell sarcoma of kidney 2 trials
-
New hope for rare childhood cancer: drug cocktail aims to shrink tumors and prevent return
Disease control Recruiting nowThis study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New stem cell approach aims to fight tough childhood cancers
Disease control Recruiting nowThis study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…
Phase 1/2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting nowThis early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill shows promise in slowing rare Cancer's growth
Disease control Recruiting nowThis study tests an experimental oral drug called cirtuvivint for people with advanced soft-tissue sarcoma that has not responded to prior treatment. About 25 participants in Spain will take the drug to see if it can stop or slow cancer growth for at least 3 months. The drug targ…
Phase 2 • Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for rare sarcoma: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called tebentafusp in people with a rare and advanced type of cancer called clear cell sarcoma. Only patients with a specific genetic marker (HLA-A*02:01) can join. The goal is to see if the drug can stop the cancer from growing for at least 24 weeks. Abou…
Phase 2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for rare cancer: targeted pill tested in advanced sarcoma
Disease control Recruiting nowThis phase 2 trial tests the drug vebreltinib in 30 people with advanced clear cell sarcoma, a rare cancer of the soft tissues. Participants take the drug as a capsule twice daily until the cancer worsens or side effects become too severe. The main goal is to see if the drug can …
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Scientists launch deep dive into rare sarcomas to unlock immune secrets
Knowledge-focused Recruiting nowThis study is collecting tumor and blood samples from 400 people with rare soft tissue sarcomas to learn how their immune system reacts to the cancer. Researchers will also track patients' health over time to see how the disease progresses. The goal is to find clues that could le…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC